Merrimack Pharmaceuticals Inc.
101 Binney Street
Cambridge
Massachusetts
02142
United States
Tel: 617-441-1000
Fax: 617-491-1386
Website: http://www.merrimackpharma.com/
Email: info@merrimackpharma.com
300 articles about Merrimack Pharmaceuticals Inc.
-
Merrimack Commences Tender Offer For Any And All Of Its Outstanding 4.50% Convertible Senior Notes Due 2020
10/13/2017
-
Merrimack Announces Settlement of Convertible Note Litigation
10/11/2017
-
Merrimack Announces Date Of One-for-Ten Reverse Stock Split
8/31/2017
-
Merrimack Augments Executive Team With Appointment Of Jean Franchi As Chief Financial Officer
8/14/2017
-
Merrimack Reports Second Quarter 2017 Financial Results
8/9/2017
-
Merrimack Announces Timing Of Second Quarter 2017 Investor Conference Call
8/2/2017
-
Merrimack Appoints Thomas Needham As Chief Business Officer
7/24/2017
-
Merrimack Announces Completion Of Enrollment In Phase II CARRIE Study Of MM-141; Data Expected In First Half Of 2018
6/19/2017
-
Merrimack Announces Expansion Of Senior Management Team With Appointment Of Sergio Santillana As Chief Medical Officer And Ellen Forest As Head Of Human Resources
6/8/2017
-
Merrimack CFO To Step Down, Effective June 9
5/26/2017
-
Merrimack Reports First Quarter 2017 Financial Results
5/10/2017
-
Merrimack Announces Timing Of First Quarter 2017 Investor Conference Call
5/3/2017
-
BioSurplus To Auction Lab Assets From Merrimack In Cambridge, Mass.
4/26/2017
-
Merrimack Appoints Daryl Drummond, Ph.D. As Head Of Research
4/17/2017
-
Merrimack Declares $140M Special Dividend In Connection With Recently Completed Asset Sale
4/6/2017
-
Merrimack Launches As New, Refocused Research & Clinical Development Company With Resources To Advance Prioritized Lead Pipeline Candidates MM-121, MM-141 And MM-310
4/3/2017
-
Ipsen Completes Acquisition Of ONIVYDE (Irinotecan Liposome Injection) And Additional Oncology Assets From Merrimack
4/3/2017
-
Merrimack Stockholders Approve Sale Of ONIVYDE And Generic Version Of DOXIL To Ipsen For Up To $1.025 Billion
3/31/2017
-
Merrimack Initiates Phase I Study Of MM-310 In Solid Tumors
3/23/2017
-
Ex-Merrimack Director Hires Prominent Boston Lawyer to Fight Insider Trading Charges
3/22/2017